Erica Whittaker
Directeur/Membre du Conseil chez Neurona Therapeutics, Inc.
Profil
Erica Whittaker is currently a Director at Neurona Therapeutics, Inc. and a Director at StrideBio, Inc. She is also a Director at SpliceBio SL, UCB Ventures (Private Equity), Rinri Therapeutics Ltd., and Exevir Bio BV.
Previously, she worked as a Research Analyst at Merrill Lynch, Pierce, Fenner & Smith Ltd.
Postes actifs de Erica Whittaker
| Sociétés | Poste | Début |
|---|---|---|
Neurona Therapeutics, Inc.
 Neurona Therapeutics, Inc. BiotechnologyHealth Technology Neurona Therapeutics, Inc. operates as a pre-clinical stage biotechnology company. It focuses on the discovery and development of cell-based therapies to treat intractable neurological disease. The company was founded by Arnold R. Kriegstein, John Rubenstein, Cory R. Nicholas, and Arturo Alvarez-Buylla and is headquartered in South San Francisco, CA. | Directeur/Membre du Conseil | 22/06/2021 |
| UCB Ventures London | Private Equity Investor | 01/10/2017 |
Exevir Bio BV
 Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium. | Directeur/Membre du Conseil | - |
StrideBio, Inc.
 StrideBio, Inc. BiotechnologyHealth Technology Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC. | Directeur/Membre du Conseil | 14/06/2018 |
Rinri Therapeutics Ltd.
 Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom. | Directeur/Membre du Conseil | 01/02/2021 |
SpliceBio SL
 SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
UCB Ventures (Private Equity)
 UCB Ventures (Private Equity) Investment ManagersFinance UCB Ventures is the venture capital arm of UCB SA and was founded in 2016. UCB Ventures is headquartered in Brussels, Belgium with additional offices in Boston, Massachusetts and London, United Kingdom. | Directeur/Membre du Conseil | - |
Anciens postes connus de Erica Whittaker
| Sociétés | Poste | Fin |
|---|---|---|
| Merrill Lynch, Pierce, Fenner & Smith Ltd. | Analyst-Equity | 01/01/2009 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Neurona Therapeutics, Inc.
Neurona Therapeutics, Inc. BiotechnologyHealth Technology Neurona Therapeutics, Inc. operates as a pre-clinical stage biotechnology company. It focuses on the discovery and development of cell-based therapies to treat intractable neurological disease. The company was founded by Arnold R. Kriegstein, John Rubenstein, Cory R. Nicholas, and Arturo Alvarez-Buylla and is headquartered in South San Francisco, CA. | Health Technology |
| Merrill Lynch, Pierce, Fenner & Smith Ltd. | Finance |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC. | Health Technology |
SpliceBio SL
SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Health Technology |
UCB Ventures (Private Equity)
UCB Ventures (Private Equity) Investment ManagersFinance UCB Ventures is the venture capital arm of UCB SA and was founded in 2016. UCB Ventures is headquartered in Brussels, Belgium with additional offices in Boston, Massachusetts and London, United Kingdom. | Finance |
| UCB Ventures London | Finance |
Rinri Therapeutics Ltd.
Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom. | Commercial Services |
Exevir Bio BV
Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium. | Health Technology |
